- Bio-Techne carries a “Moderate Buy” consensus from 13 analysts, with an average price target of $70.58, implying about 15% upside.
- Recent positive revisions include TD Cowen (Oct. 14, target raised from $65 to $70, Strong Buy), Evercore ISI (Oct. 7, $60 to $72, Buy), and RBC
-